Filing Date Form TypeDescription   
   
Data pager
12
 Page 1 of 2, items 1 to 13 of 15.
2022-08-1210-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-22-047246 (34 Act)  Size: 3 MB
2022-05-1210-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-22-025962 (34 Act)  Size: 3 MB
2021-11-1010-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-21-058065 (34 Act)  Size: 3 MB
2021-08-1310-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-21-042324 (34 Act)  Size: 3 MB
2021-05-1410-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-21-026314 (34 Act)  Size: 2 MB
2020-11-1010-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-20-036128 (34 Act)  Size: 3 MB
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-20-021119 (34 Act)  Size: 2 MB
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-20-011609 (34 Act)  Size: 2 MB
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-19-022496 (34 Act)  Size: 3 MB
2019-08-1210-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-19-015316 (34 Act)  Size: 2 MB
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001615774-19-007745 (34 Act)  Size: 2 MB
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001615774-18-012135 (34 Act)  Size: 2 MB
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001615774-18-008047 (34 Act)  Size: 2 MB


Sensus Healthcare to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09/09/2022 12:00 PM

BOCA RATON, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.  The hybrid format includes in-person meetings in New York City and will be holding one-on-one meetings.  A webcast of the presentation will be available on-demand beginning September 12, 2022 at 7:00 a.m. Eastern time on the investors section of Sensus Healthcare’s website or at this link.


Sensus Healthcare Adds Dr. Mohammad K. Khan to Medical Advisory Board
09/07/2022 12:00 PM

Addition of World-Renowned Radiation Oncologist Deepens Pool of Expertise
Addition of World-Renowned Radiation Oncologist Deepens Pool of Expertise

Sensus Healthcare Launches Upgrade to its SRT-100 Vision System with New State-of-the-Art Ultrasound Capabilities
08/09/2022 8:25 PM

Includes a new ergonomic probe to operate in ideal MHz range to view all layers of skin
Includes a new ergonomic probe to operate in ideal MHz range to view all layers of skin

Sensus Healthcare Second Quarter 2022 Financial Results Feature Revenue Growth of 124%
08/04/2022 8:05 PM

Diluted EPS of $0.21 compares with $(0.02) for the year-ago quarter 
Affirms expectations for full-year profitability


Sensus Healthcare Takes Order for 10 TransDermal Infusion Systems™ Supporting Hair Enhancement Centers Expansion Along with U.SK Under Skin’s Hair-Health Serum
07/27/2022 12:00 PM

BOCA RATON, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC), a rapidly-growing chain of Texas-based hair loss treatment centers. The Systems will be used to non-invasively deliver U.SK Under Skin’s hair-health serum Skin Savers Hair™.  U.SK Under Skin is a subsidiary of privately-held EMS Pharma, the largest pharmaceutical company in Brazil and itself a subsidiary of Grupo NC, one of Brazil’s largest conglomerates.


Sensus Healthcare to Host Second Quarter 2022 Financial Results and Business Update Conference Call on August 4, 2022
07/26/2022 12:00 PM

BOCA RATON, Fla., July 26, 2022 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 4, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Colorado State University College of Veterinary Medicine and Biomedical Sciences Acquires Second SRT System from Sensus Healthcare
07/20/2022 12:00 PM

Researchers at the Johnson Family Equine Hospital to study superficial radiation therapy in horses following the University’s successful use in companion animals


Correction: Sensus Healthcare to Participate in the H.C. Wainwright Global Investment Conference
05/23/2022 7:56 PM

BOCA RATON, Fla, May 23, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be participating in the H.C. Wainwright Global Investment Conference taking place virtually and in-person at the Fontainebleau Miami Beach May 23-26, 2022. 


Sensus Healthcare to Participate in the H.C. Wainwright Global Investment Conference
05/18/2022 8:05 PM

BOCA RATON, Fla, May 18, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be participating in the H.C. Wainwright Global Investment Conference taking place virtually and in-person at the Fontainebleau Miami Beach May 23-26, 2022. 


Sensus Healthcare First Quarter 2022 Financial Results Feature Revenue Growth of 237%
05/05/2022 8:05 PM

Diluted EPS from operations of $0.20 compare with $(0.07) in the year-ago quarter


Sensus Healthcare to Host First Quarter 2022 Financial Results and Business Update Conference Call on May 5, 2022
04/21/2022 12:00 PM

BOCA RATON, Fla, April 21, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 5, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Mata Mata Turtle with Squamous Cell Carcinoma Successfully Treated with Sensus Healthcare’s SRT System by Colorado State University Veterinarian
03/24/2022 12:00 PM

Joins multiple companion animals and a horse successfully treated with SRT
Joins multiple companion animals and a horse successfully treated with SRT

Sensus Healthcare to Present at Two Investment Conferences in March
03/09/2022 9:05 PM

BOCA RATON, Fla. , March 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be presenting at the following investment conferences during March:


Sensus Healthcare Announces Share Repurchase Program
03/09/2022 1:00 PM

BOCA RATON, Fla, March 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that its Board of Directors has authorized a program to purchase up to $3,000,000 of shares of its Common Stock. 


Sensus Healthcare Sells its Sculptura™ Assets to Empyrean Medical Systems for $15 Million in Cash
03/02/2022 1:00 PM

Sale permits Sensus to focus on the core dermatology market while providing capital for channel expansion


Sensus Healthcare Reports Record Sales and Earnings for the 2021 Fourth Quarter
02/10/2022 9:05 PM

4Q21 diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively


Sensus Healthcare Prepares Organization for Long-term Growth with Three Promotions
01/31/2022 9:05 PM

Michael J. Sardano named President, Christopher Machuzak and Jeffrey Starling named Regional Vice Presidents of Sales
Michael J. Sardano named President, Christopher Machuzak and Jeffrey Starling named Regional Vice Presidents of Sales

Sensus Healthcare to Host Fourth Quarter 2021 Financial Results and Business Update Conference Call on February 10, 2022
01/26/2022 1:30 PM

BOCA RATON, Fla, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 10, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Sensus Healthcare to Present at the H.C. Wainwright BioConnect Virtual Conference
01/06/2022 6:08 PM

Company Management Available for 1x1 Meetings Concurrent with the 40th Annual J.P. Morgan Healthcare Conference January 10-14
Company Management Available for 1x1 Meetings Concurrent with the 40th Annual J.P. Morgan Healthcare Conference January 10-14

Sensus Healthcare Expects Record 4Q 2021 Sales and Continued Growth in 1Q 2022; Profiles New Product at the 2022 Winter Clinical Dermatology Conference
01/05/2022 1:00 PM

Expects profitability for the 2021 fourth quarter and full year Physician KOL presentation at the Winter Clinical to highlight the TransDermal Infusion System™
Expects profitability for the 2021 fourth quarter and full year Physician KOL presentation at the Winter Clinical to highlight the TransDermal Infusion System™